Přehled o publikaci
2023
Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening.
DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA; Michal ŠMÍDA et al.Basic information
Original name
Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening.
Authors
DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA and Michal ŠMÍDA
Edition
XX. International Workshop on CLL (iwCLL 2023), Boston, USA, 2023
Other information
Language
English
Type of outcome
Konferenční abstrakta
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Marked to be transferred to RIV
No
Organization
Středoevropský technologický institut – Repository – Repository
Keywords in English
CD20 antigen; rituximab; therapy of B-cell malignancies; CRISPR/Cas9 knockout screening
Links
MUNI/A/1224/2022, interní kód Repo.
Changed: 6/1/2026 00:51, RNDr. Daniel Jakubík
Abstract
In the original language
CD20 antigen has been used as a target of monoclonal antibodies (mAb) such as rituximab (RTX) in the therapy of B-cell malignancies for more than two decades. However, CLL B cells tend to express lower levels of CD20 on their surface or downregulate it following the mAb treatment, resulting in mAb resistance and subsequently therapy failure. Therefore, it is crucial to investigate the regulation of CD20 in order to restore sensitivity to anti-CD20 mAb and enhance its efficacy. The aim of this project was to perform genome-wide CRISPR/Cas9 knockout screening to identify genes whose disruption upregulates CD20 surface expression in the resistant cells with low CD20 levels.
